Dolutegravir noninferior to a ritonavir-boosted protease inhibitor regimen for treating HIV

1. In the randomized controlled trial, dolutegravir treatment was noninferior to a regimen containing a ritonavir-boosted protease inhibitor (PI) for treating human immunodeficiency virus (HIV). 2. Dolutegravir treatment for HIV was not associated with an increased risk of adverse events as compared to ritonavir-boosted treatment. Evidence Rating Level: 1 (Excellent) Study Rundown: Currently, the World

Related Keywords

Kenya , ,Minute Medicine Inc ,Drug Administration ,World Health Organization ,Rating Level ,Second Line Treatment ,Chronic Disease ,Dolutegravir ,Shiv ,Human Immunodeficiency Virus Hiv ,Infectious Disease ,Nnrti ,Non Nucleoside Reverse Transcriptase Inhibitor Nnrti ,Nucleoside Nucleotide Reverse Transcriptase Inhibitors Nrtis ,Public Health ,Ritonavir Boosted Protease Inhibitor ,